Objective Response Rate
11 clinical trials · Condition
◉ Watch Objective Response Rate
| Record | Firm | Date |
|---|---|---|
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer (NCT05310383) | Lei Li | 2022-03-27 |
| Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma (NCT04850560) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-05-18 |
| Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer (NCT04670978) | Shandong University | 2021-03-31 |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma (NCT04664244) | Lei Li | 2020-12-19 |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas (NCT04635956) | Lei Li | 2020-11-15 |
| Real-world Study for Patients With Advanced Hepatobiliary Tumors (NCT03892577) | Peking Union Medical College Hospital | 2017-07-01 |
Track Objective Response Rate automatically
Every clearance here is in the API, with alerts when new ones post.